tivozanib (Pending FDA Approval)

Brand and Other Names:Fotivda
  • Print

Dosing & Uses

Renal Cell Carcinoma

VEGF inhibitor pending FDA approval for renal cell carcinoma

Next:

Pharmacology

Mechanism of Action

Selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) receptors; inhibits VEGF1, VEGF2, and VEGF3, thereby blocking these receptors role in cancer angiogenesis

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.